Barclays analyst Gena Wang raised the firm’s price target on Cytokinetics (CYTK) to $82 from $71 and keeps an Overweight rating on the shares ahead of aficamten Phase 3 ACACIA data in in nonobstructive hypertrophic cardiomyopathy. The firm sees over a 75% probability of a of positive study given that only one of the dual primary endpoints would need to hit statistical significance. Barclays expects aficamten to become the first approved drug for nonobstructive hypertrophic cardiomyopathy. and preferred drug over Camzyos.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $56 from $52 at BofA
- Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
- Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
- Cytokinetics’ Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock Outlook
- Cytokinetics presents data related to aficamten at HFSA Meeting 2025